BMY - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים Bristol-Myers Squibb

לוגו גרפי של bms.com (BMY)

Pressure on operating leverage is increasing due to the loss of patent protection for legacy drugs, yet Bristol-Myers Squibb (BMY) maintains physician confidence through its authority in cardiology and oncology. A broad portfolio of proven medications ensures high margins, as evidenced by the current 12-month trailing revenue dynamics, where the current value stands at 4.10, confirming the revenue resilience of this behemoth.

BMY - צמיחת מכירות משנה לשנה (TTM) BMS בטווח 11.02.2024 - 18.11.2026

Bristol-Myers Squibb - פילוחים אנליטיים ומדדי מפתח (BMY)

- מחיר ותחזית קונצנזוס למחירים:
ניתוח כל מדדי החברה:Bristol-Myers Squibb
מוצר ממותג של Bristol-Myers Squibb Co.

Bristol-Myers Squibb (BMY) revenues depend on the performance of blockbuster drugs and the success of M&A deals aimed at mitigating patent risks. By analyzing year-over-year revenue changes over the trailing twelve months (TTM), an investor can observe a smoothed business expansion percentage stripped of market noise, where stable growth confirms the efficacy of new drugs, while sharp spikes may signal an overvaluation of the asset.